latest news releases from the newsroom
Keller Rohrback L.L.P.
Keller Rohrback L.L.P. Announces Class Action Filed On Behalf of Participants in New Mexico's 529 College Savings Plans
SEATTLE, July 14, 2009 (GLOBE NEWSWIRE) -- Keller Rohrback L.L.P. (www.krclassaction.com) announces that it has filed a class action Complaint against the Education Trust Board of New Mexico and the Education Plan Trust of New Mexico (collectively, the "State") for breach of contract involving its 529 college savings plans: "Education Plan"; and "Scholar'sEdge Plan." The Complaint was filed in Santa Fe County First Judicial District Court on behalf of a class of all persons that entered into or maintained an Education Plan Participation Agreement from June 25, 2007 through the present and who suffered losses in the 529 Plans related to the Trust's fixed-income assets. Santa Fe attorney John Bienvenu is co-counsel in the case.
Second Quarter 2009 Earnings Conference Call Announced by Capital Bank Corporation
RALEIGH, N.C., July 14, 2009 (GLOBE NEWSWIRE) -- Capital Bank Corporation (Nasdaq:CBKN) will host a conference call on Wednesday, July 22, 2009 beginning at 11:00 a.m. Eastern Daylight Time. The purpose of the call will be to provide interested parties with financial information regarding the quarter ended June 30, 2009. The Company plans to release financial results for the quarter ended June 30, 2009 on Tuesday, July 21, 2009.
XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
BERKELEY, Calif., July 14, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced positive results from single dose and multiple dose subcutaneous arms of the randomized, placebo-controlled U.S. Phase 1 clinical trial of XOMA 052 in Type 2 diabetes patients. Of the 98 patients evaluated in different parts of the Phase 1 clinical trial, XOMA is reporting today on the 26 patients who received active drug in both single and multiple doses by subcutaneous route of administration and all 17 placebo patients. The results continue to demonstrate that XOMA 052 is well tolerated in patients. Further, a multiple dose regimen of XOMA 052 showed clinically meaningful reductions in glycosylated hemoglobin, HbA1c, and high sensitivity C-reactive protein, hsCRP, compared to a single dose regimen. Generally, a more consistent response was seen across patients in the multiple dose regimen compared to single dose regimen. New positive biological activity was observed with sustained improvements noted in fasting blood glucose, with a reduction of 29 mg/dL at day 84, equating to approximately a 1% reduction in HbA1c, and standard biomarkers of systemic inflammation and cardiovascular risk. Pharmacokinetic results continue to support monthly or less frequent dosing and drug bioavailability in patients by subcutaneous injection was 62-70% compared to IV administration. These Phase 1 results support XOMA's plan to begin Phase 2 testing of XOMA 052 in Type 2 diabetes in the current quarter.
Cutera, Inc. to Announce Results for the Second Quarter Ended June 30, 2009
BRISBANE, Calif., July 14, 2009 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, will announce results for the second quarter ended June 30, 2009 on Monday, August 3, 2009, after market close. The Company will also host a conference call to discuss these results with additional comments and details. Participating on the call will be Kevin Connors, President and Chief Executive Officer, and Ron Santilli, Chief Financial Officer.
Synaptics to Report Fourth Quarter Results On July 30
SANTA CLARA, Calif., July 14, 2009 (GLOBE NEWSWIRE) -- Synaptics(r) Incorporated (Nasdaq:SYNA), a leading developer of human interface solutions for mobile computing, communications, and entertainment devices, announced today that it will report financial results for the fourth quarter and fiscal year 2009 on Thursday, July 30, 2009, after the close of market. The company will host a corresponding conference call for analysts and investors at 2:00 p.m. PT (5:00 p.m. ET), during which management may discuss forward-looking information.